Light and challenges:Advances in targeted therapy for glioma
10.3969/j.issn.1002-0152.2025.01.001
- VernacularTitle:光明与挑战:胶质瘤靶向治疗前沿进展
- Author:
Dongyuan SU
1
;
Chunsheng KANG
1
Author Information
1. 天津医科大学总医院,天津市神经病学研究所神经肿瘤研究室(天津 300052)
- Publication Type:Journal Article
- Keywords:
Glioma;
Targeted therapy;
Molecular biomarkers;
Computer-aided drug design;
PTRF/Cavin1;
HOTAIR;
MET
- From:
Chinese Journal of Nervous and Mental Diseases
2025;51(1):1-7
- CountryChina
- Language:Chinese
-
Abstract:
Glioma is the most common malignant primary brain tumor in adults,characterized by rapid malignant progression,high recurrence rates,and high mortality.The main treatment methods are surgery followed by radiotherapy and chemotherapy.Temozolomide,as the first-line drug for glioma treatment,is exposed to increasingly severe issues with drug resistance,which significantly impacts the efficacy and prognosis for glioma patients.With advancements in molecular biomarker detection and the emergence of precision medicine,targeted and individualized treatment strategies for glioma patients are evolving rapidly.The discovery of new glioma biomarkers,such as long non-coding RNA HOTAIR(HOX antisense intergenic RNA),polymerase Ⅰ and transcript release factor(PTRF/Cavin1),and MET,along with the application of new technologies like computer-aided drug design(CADD),has ushered in a new era for the design and development of targeted drugs for glioma.Due to the heterogeneity of glioma,the effectiveness of single-target drugs is limited.In the future,a combination of physical,chemical,and biological interventions will be the breakthrough direction for glioma treatment.
